Objective: Eating until one is 80% full is considered a healthy dietary practice in Japan. This study examined the relationship between this behavior and energy intake and types and quantities of foods consumed to examine its beneficial effects.
Methods: This study relied on dietary records and self-administered questionnaires completed by 330 users of a health-management website in November 2012. ANOVA was performed to examine the relationship between eating until one is 80% full and intake.
Results: Men who always ate until they were 80% full consumed less energy than those who did not (mean [SD]; always: 1997.3 [356.7] kcal; rarely/never: 2448.9 [637.1] kcal; p<0.05). Moreover, men who ate until they were 80% full consumed fewer servings of grain dishes (always: 3.7 [0.9] servings; rarely/never: 5.1 [1.9] servings; p<0.05) and more servings of vegetable dishes (always: 5.9 [2.2] servings; rarely/never: 4.0 [2.3] servings, p<0.05) than those who did not.
Conclusion: Men who ate until they were 80% full consumed less energy and more vegetable dishes than those who did not, suggesting that eating until one is 80% full is associated with healthy dietary habits among men.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eatbeh.2015.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
N-terminal fragment shedding contributes to signaling of the full-length adhesion receptor ADGRL3.
J Biol Chem
January 2025
Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA. Electronic address:
Most adhesion GPCRs undergo autoproteolytic cleavage during receptor biosynthesis, resulting in non-covalently bound N- and C-terminal fragments (NTF and CTF) that remain associated during receptor trafficking to the plasma membrane. While substantial evidence supports increased G protein signaling when just the CTF is expressed, there is an ongoing debate about whether NTF removal is required to initiate signaling in the context of the wild-type receptor. Here, we use adhesion GPCR latrophilin-3 (ADGRL3) as a model receptor to investigate tethered agonist-mediated activation.
View Article and Find Full Text PDFBackground: In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1-9 years in Niger.
Methods: In this three-arm, open-label, cluster-randomised trial, 63 clusters of one to four villages in Niger were randomly assigned (3:3:1) using block randomisation to receive campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign.
Formative evaluation of a mobile chat-based intervention (ChatEx) for promoting exercise behaviour in older cancer survivors.
Eur J Oncol Nurs
December 2024
School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Purpose: To conduct a formative evaluation of ChatEx to increase and maintain exercise among older cancer survivors.
Methods: ChatEx is a blended intervention involving 12 weeks of theory-based instant messages and two in-person training sessions. This pilot study comprises three phases: (1)intervention development: developing a message library reviewed by experts; (2)message library pretesting: exploring the views of older cancer survivors toward the message library and making modifications (n = 20); and (3)intervention pilot testing: piloting the ChatEx using a non-randomized quasi-experimental design using quantitative and qualitative methods among cancer survivors aged 65+ who do not meet current exercise guidelines and have completed treatment (n = 40).
[The challenges of new digital technologies on the Moroccan health system : Case of the cardiology departement -B- University Hospital Center Ibn Sina Rabat].
Ann Cardiol Angeiol (Paris)
January 2025
Faculte des Sciences Juridiques, Economiques et Sociales, Département d'Economie et de Gestion, Souissi, Rabat, Maroc.
Introduction: We live in the era of information technology (IT) innovations in the health sector, this has led to the appropriation of new organizational models which are profoundly changing the practice of medicine. Our study aims to determine the challenges of new digital technologies in the Moroccan health system, the case of the cardiology department - B - of the Ibn Sina University Hospital Center.
Materials And Methods: This is a single-center observational descriptive-analytical study carried out at the level of the cardiology department - B- for 6 months, from September 1, 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!